Evaluation of short-term efficacy of 18F-FDG PET/CT in children with neuroblastoma
MA Qiuman1, LI Yanshan2, WANG Jun2, MIAO Lixia2, SUN Yanfeng2, LIU Hongyan2, YUAN Hailian2, ZHANG Xianglan2, and LIU Qiuling1,2
1.Graduate School of Anhui Medical University, Hefei 230032, China; 2. Department of Pediatrics,The General Hospital of Chinese People’s Armed Police Force, Beijing 100039, China
Abstract：Objective To investigate the clinical value in the evaluation of the short-term efficacy of 18F-FDG PET/CT in children with neuroblastoma (NB).Methods Clinical data of 14 NB patients undergoing 18F-FDG PET/CT examination were recruited from April 2012 to April 2015 in this hospital. We evaluated the therapeutic efficacy in NB children and detected recurrent lesions.Results 14 NB children received totally 18 times 18F-FDG PET/CT examinations. Among them, 8 cases showed different degree and different parts with abnormal increased uptake of FDG, which guided to adjusting clinical treatment promptly.18F-FDG PET/CT changed one case’s stage, increasing from the initial stage Ⅳs to stage Ⅳ. 4 children who suffered relapse had a total of 17 lesions. The detection rate of 18F-FDG PET/CT for recurrent and metastatic lesions was 88.2% (15/17), missing one small intracranial metastasis and one case of bone marrow micro-metastasis.Conclusions 18F-FDG PET/CT has an important value in the evaluation of the short-term efficacy of NB children, and can be used as follow-up examination of NB in children.
马秋满，李彦珊，王 军，苗丽霞，孙岩峰，刘红艳，袁海莲，张向兰，刘秋玲. 18F-FDG PET/CT对儿童神经母细胞瘤近期疗效评估的应用价值[J]. 武警医学, 2016, 27(7): 661-665.
MA Qiuman, LI Yanshan, WANG Jun, MIAO Lixia, SUN Yanfeng, LIU Hongyan, YUAN Hailian, ZHANG Xianglan, and LIU Qiuling. Evaluation of short-term efficacy of 18F-FDG PET/CT in children with neuroblastoma. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(7): 661-665.
Vo K T, Matthay K K, Neuhaus J, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the intemational neuroblastoma risk group project [J]. J Clin Oncol, 2014, 32(28): 3169-3176.
[2]
Dhull V S, Sharma P, Patel C, et al. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy [J]. Nucl Med Commun, 2015, 36(10) : 1007-1013.
Ikeda H, Iehara T, Tsuchida Y, et al. Experience with international neuroblastoma staging system and pathology classification [J]. Br J Cancer, 2002, 86(7): 1110-1116.
[6]
Monclair T,Brodeur G M,Ambros P F,et al. The International Neuroblastoma Risk Group (INRG) staging system:an INRG Task Force Report [J] . J Clin Oncol, 2009, 27(2): 298-303.
Davidoff A M. Neuroblastoma[J]. Semin Pediatr Surg, 2012, 21(1): 2-14.
[9]
Pearson A D, Pinkerton C R, Lewis I J, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomized trial [J]. Lancet Oncol, 2008, 9(3): 247-256.
[10]
Min J W, Um S W, Yim J J, et al. The role of whole-body FDG PET/CT, 99mTc MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer [J]. J Korean Med Sci, 2009, 24(2): 275-280.
Choi Y J, Hwang H S, Kim H J, et al.18F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy [J]. Ann Nucl Med, 2014, 28(4): 304-313.
2016, Vol. 27 
